Clinical Trial Update: Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial sponsored by The University of Hong Kong is evaluating the SGLT2 inhibitor dapagliflozin (Forxiga) to improve cardio-pulmonary status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Heart Disease
• Pulmonary Regurgitation
• Tetralogy of Fallot

Drugs mentioned

• Forxiga (dapagliflozin)

Snippet

Sponsor: The University of Hong Kong | Conditions: Congenital Heart Disease, Repaired Tetralogy of Fallot (rTOF) | Phase 4 | Status: RECRUITING